PAR 2.13% 23.0¢ paradigm biopharmaceuticals limited..

Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-378

  1. 118 Posts.
    lightbulb Created with Sketch. 10
    Intention to treat analysis.
    Chris NicksonNov 3, 2020 HOMECCC
    Reviewed and revised 5 July 2014
    OVERVIEW:
    Intention to treat (ITT) analysis means all patients who were enrolled and randomly allocated to treatment are included in the analysis and are analysed in the groups to which they were randomized i.e. “once randomized, always analyzed”
    Inclusion occurs regardless of deviations that may happen after randomisation, such as: protocol violations (e.g. those who received the comparative treatment or other treatments, rather than the allocated treatment)losses to follow up withdrawals from the study non-compliance refusal of the allocated treatmentI TT analysis preserves the prognostic balance generated by the original random treatment allocation this type of analysis is in contrast to ‘per protocol’ analysis and ‘as treated’ analysis
    PROS
    supported by the CONSORT statement more reliable estimate of true treatment effectiveness by replicating what happens in the ‘real world’ (e.g. noncompliance and protocol violations commonly affect therapies); treatment effectiveness is not the same as the effectiveness of an assigned treatment in an RCT simplifies the task of dealing with suspicious outcomes (guards against conscious or unconscious attempts to influence the results of the study by excluding odd outcomes)prevents bias when incomplete data is related to outcome preserves baseline balance between groups minimises Type 1 errors (‘false positives’)preserves sample size (dropouts etc would otherwise decrease the sample size and decrease statistical power)When the ITT and per-protocol analyses come to the same conclusions, confidence in the study results is increased
    CONS
    estimate of treatment effect is conservative because of dilution due to noncompliance and more prone to Type 2 errors (‘false negatives’)heterogeneity is introduced when noncompliants, dropouts and compliant subjects are mixed togetherdoes not assess treatment efficacy accurately unless there is negligible protocol violations, etcprotocol violations and poorly conducted trials may cause the results obtained from two different treatment groups to appear similar so ITT analysis alone is inappropriate for non-inferiority trials
    ALTERNATIVES
    ‘As treated’ analysis. An “as treated” analysis classifies RCT participants according to the treatment that they received rather than according to the treatment that they were assigned tosubject to confounding in the same way as an observational study‘Per protocol’ analysisaka ‘on treatment’ analysisonly includes individuals who adhered to the clinical trial instructions as specified in the study protocolsubject to selection bias due to cross-over and loss to follow upper protocol analysis may be appropriate when analysing adverse events in drug trials, as it can be argued that side-effects of actual treatment received is clinically relevant ‘modified ITT’ analysis allows the exclusion of some randomized subjects in a justified way (e.g. patients who were deemed ineligible after randomization or certain patients who never started treatment) definitions used are irregular and arbitrary; consistent guidelines for its application are lacking a subjective approach in entry criteria may lead to confusion, inaccurate results and bias
    References and LinksJournal articlesFergusson D, Aaron SD, Guyatt G, Hébert P. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ. 2002 Sep 21;325(7365):652-4. PMC1124168.Gupta SK. Intention-to-treat concept: A review. Perspect Clin Res. 2011 Jul;2(3):109-12. PMC3159210.Hernán MA, Hernández-Díaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials. 2012 Feb;9(1):48-55. PMC3731071.Montori VM, Guyatt GH. Intention-to-treat principle. CMAJ. 2001 Nov 13;165(10):1339-41. PMC81628.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
23.0¢
Change
-0.005(2.13%)
Mkt cap ! $80.45M
Open High Low Value Volume
23.5¢ 24.0¢ 23.0¢ $63.43K 270.4K

Buyers (Bids)

No. Vol. Price($)
10 213534 23.0¢
 

Sellers (Offers)

Price($) Vol. No.
23.5¢ 76890 2
View Market Depth
Last trade - 16.10pm 05/09/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.